Cure My Disease

Don't miss your cure!

 Log in / Sign up

Tailoring radiation to each Patient's anatomy may spare healthy tissue

NCT ID NCT06230549

Symptom relief Sponsor: University Hospital, Essen Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Oct 20, 2026 · Last updated Oct 21, 2026 · Updated 1 time

Summary

Researchers are testing adaptive radiotherapy, a technique that reshapes the radiation plan to match each patient's anatomy before treatment, in women with locally advanced gynecological cancers such as cervical, endometrial, or vaginal tumors. The trial randomly assigns participants to adaptive radiotherapy or standard radiotherapy. It measures bowel, bladder, skin, and lymph side effects, and tracks survival and cancer progression. The goal is to see whether adapting the radiation plan reduces harm to healthy tissue without compromising cancer control.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
adaptive radiotherapy, a form of image-guided radiation that adjusts the dose plan to each patient's anatomy before treatment
What this could lead to
If it works, adaptive radiotherapy could become a standard option that spares healthy tissue and lowers side effects for women receiving pelvic radiation for gynecological cancers.
What could go wrong
The trial is small, with 30 participants, and compares one technical approach against standard radiotherapy. It may not show a clear difference in side effects, and the results may not apply to all gynecological cancers or treatment settings.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

30 people

The number who actually took part.

Started

Jan 2024

Finished

Oct 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: ECOG 0-1 confirmation by histophatology MR of the pelvis staging Exclusion Criteria: Recurrent disease Prior Radiotherapy in pelvic region stage pM1 or cM1

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Adaptive radiation therapy are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cervical carcinoma Uterine Cervical Neoplasms

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Adaptive radiation therapy Adaptive radiotherapy Cervical carcinoma Curative treatment Gynecological tumor Image guided radiotherapy Optimization Radiation

Contacts and locations

Locations

  • Department for Radiotherapy, University Hospital Essen, National Center for Tumor Diseases (NCT) West

    Essen, Germany / NRW, 45147, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.